BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 19922070)

  • 21. Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.
    Kato H; Samukawa S; Takahashi H; Nakajima H
    J Infect Chemother; 2019 Nov; 25(11):920-924. PubMed ID: 31300379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium.
    Maldonado YA; Araneta RG; Hersh AL
    Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model.
    Brun-Pascaud M; Chau F; Garry L; Farinotti R; Derouin F; Girard PM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):201-7. PubMed ID: 8898664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.
    Alvarez-Martínez MJ; Miró JM; Valls ME; Mas J; de la Bellacasa JP; Sued O; Solé M; Rivas PV; de Lazzari E; Benito N; García F; Agustí C; Wilson PE; Gatell JM; Jiménez de Anta MT; Meshnick SR; Moreno A
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):60-5. PubMed ID: 20727472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction.
    Pyle RC; Butterfield JH; Volcheck GW; Podjasek JC; Rank MA; Li JT; Harish A; Poe KL; Park MA
    J Allergy Clin Immunol Pract; 2014; 2(1):52-8. PubMed ID: 24565769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retrospective investigation of side effects and prognoses of moderate-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia that developed in patients with autoimmune diseases].
    Shibata T; Tonooka K; Tsuchida K; Mitomi H; Shibata T; Katsuyama N
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):213-8. PubMed ID: 27320937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
    Podzamczer D; Santín M; Jimenez J; Casanova A; Bolao F; Gudiol GR
    AIDS; 1993 Apr; 7(4):501-6. PubMed ID: 8507417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.
    Kofteridis DP; Valachis A; Velegraki M; Antoniou M; Christofaki M; Vrentzos GE; Andrianaki AM; Samonis G
    J Infect Chemother; 2014 Jul; 20(7):412-6. PubMed ID: 24767467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trimethoprim-sulfamethoxazole and hypouricemia.
    Chertow GM; Seifter JL; Christiansen CL; O'Donnell WJ
    Clin Nephrol; 1996 Sep; 46(3):193-8. PubMed ID: 8879855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral trimethoprim-sulphamethoxazole levels in stable HIV-infected children.
    Zar HJ; Langdon G; Apolles P; Eley B; Hussey G; Smith P
    S Afr Med J; 2006 Jul; 96(7):627-9. PubMed ID: 16909188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
    Cook DE; Kossey JL
    Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group.
    Bozzette SA; Forthal D; Sattler FR; Kemper C; Richman DD; Tilles JG; Leedom J; McCutchan JA
    Am J Med; 1995 Feb; 98(2):177-82. PubMed ID: 7847434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.
    Agrawal AK; Chang PP; Feusner J
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):e1-4. PubMed ID: 21102354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer.
    Caselli D; Petris MG; Rondelli R; Carraro F; Colombini A; Muggeo P; Ziino O; Melchionda F; Russo G; Pierani P; Soncini E; DeSantis R; Zanazzo G; Barone A; Cesaro S; Cellini M; Mura R; Milano GM; Meazza C; Cicalese MP; Tropia S; De Masi S; Castagnola E; Aricò M;
    J Pediatr; 2014 Feb; 164(2):389-92.e1. PubMed ID: 24252793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trimethoprim-sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: case report and review of the literature.
    Walker S; Norwood J; Thornton C; Schaberg D
    Am J Med Sci; 2006 Jun; 331(6):339-41. PubMed ID: 16775445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.